Despite record investment levels exceeding US$200 billion annually, the return on investment for research & development (R&D) in the pharma industry is in decline.
According to Deloitte's 2024 pharmaceutical innovation report, [1] development costs for a single drug now average $2.2 billion, while timelines stretch beyond a decade. For industry leaders navigating this challenging landscape, the solution lies not in working harder, but smarter, harnessing strategic partnerships that deliver cost-effective drug development solutions.
What’s more, pharmaceutical R&D productivity has actually been on a downward trajectory for the last 20 years. The phenomenon is known as ‘Eroom's Law’, and works quite literally like Moore's Law in reverse: while computing power doubles every 2 years, the number of new drugs approved per billion dollars spent has halved approximately every 9 years. This illustrates how efficiency in drug discovery has inversely tracked against technological advancement.
